Researchers at the University of California at Los Angeles say they have developed a new test for prostate cancer that is "more sensitive and more specific" than the usual test for prostate-specific antigen, the UCLA Health System says in a news release on a new, peer-reviewed study.
"The conventional PSA test for prostate cancer has been used for nearly 30 years and is not specific enough in delineating between malignancies and non-malignant diseases of the prostate, such as benign prostatic hyperplasia (BPH), an enlarging of the prostate common in aging men that increases PSA levels," the release said, citing urology professor Gang Zeng, senior author of the study, published in the May issue of the Journal of Translational Medicine.
The new test "measures levels of PSA as well as six specific antibodies found in the blood of men with the disease," the release says. "The test, called the A+PSA assay, also reduced the rate of false-positives, tests that indicate the presence of cancer when no disease is actually present." For more from Newswise, click here.
"The conventional PSA test for prostate cancer has been used for nearly 30 years and is not specific enough in delineating between malignancies and non-malignant diseases of the prostate, such as benign prostatic hyperplasia (BPH), an enlarging of the prostate common in aging men that increases PSA levels," the release said, citing urology professor Gang Zeng, senior author of the study, published in the May issue of the Journal of Translational Medicine.
The new test "measures levels of PSA as well as six specific antibodies found in the blood of men with the disease," the release says. "The test, called the A+PSA assay, also reduced the rate of false-positives, tests that indicate the presence of cancer when no disease is actually present." For more from Newswise, click here.
No comments:
Post a Comment